Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced positive top-line data from its Phase 1 trial of TCN-202, which was discovered using Theraclone's I-STARTM platform.
http://www.businesswire.com/news/topix/20130402005302/en
http://www.businesswire.com/news/topix/20130402005302/en
No comments:
Post a Comment